With resurgence of the coronavirus and emergence of more contagious strains, COVID-19 challenges, but also opportunities, lie ahead for medical device and diagnostics companies. | Wall Street analysts questioned whether the lower-than-expected rates are final and what the prospects are for renegotiation. Shares of market leader iRhythm fell over 32% on Friday. | Q&A Michael Coyle will try to build off the cardiac monitoring company's recent success amid a telehealth boom. Shares have jumped by over 175% in the last 12 months. | The findings add to a debate on to how to use the fast-acting tests and their potential to reduce virus spread by enabling interventions. Still, questions remain about how well these diagnostics perform on asymptomatic people. | CEO Robert Ford said the company exited 2020 with "tremendous momentum" and forecast 35% growth for this year. | CEO Alex Gorsky predicted challenges to persist in 2021 but suggested that improvement is in sight. "The resiliency and the ability of hospital systems to continue with elective surgeries has improved quite significantly," he said. | Double-digit growth in China was offset by hits in business in the U.S. and Europe. CEO Kevin Lobo told investors after volumes rebounded through October, large declines began in November and December. | Recommended For You Improve your recommendations: click here to update your profile. Deep Dive Companies have zeroed in on TAVR in recent years, but in 2021 and beyond, experts and industry are looking to the mitral market for the next big structural heart splash. | Deep Dive As tech and data sharing become more pervasive, healthcare will likely pivot to being more predictive and telehealth will evolve, giving rise to new modalities of care. This will force companies to invest more in cybersecurity. | From Our Library Webinar - on demand Irdeto | Webinar - on demand IQVIA | View all resources Best of What We're Reading The Guardian | 360Dx | Reuters | USA TODAY | MedPage Today | MedCity News | Dive Into a Topic |
0 Comments